NASDAQ:IRD Opus Genetics (IRD) Stock Price, News & Analysis $4.76 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$4.73 -0.03 (-0.63%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Opus Genetics Stock (NASDAQ:IRD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Opus Genetics alerts:Sign Up Key Stats Today's Range$4.70▼$4.9350-Day Range$2.92▼$6.0752-Week Range$1.50▼$7.07Volume1.24 million shsAverage Volume5.21 million shsMarket Capitalization$393.41 millionP/E RatioN/ADividend YieldN/APrice Target$11.92Consensus RatingModerate Buy Company Overview Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs), a group of rare genetic disorders that can cause progressive vision loss or blindness. The company aims to address conditions for which treatment options are limited or unavailable by developing therapies designed to correct or replace disease-causing genetic defects in retinal cells. Opus Genetics’ pipeline includes investigational programs for genetically defined retinal disorders, including rhodopsin-associated autosomal dominant retinitis pigmentosa and BEST1-related retinal disease. Its programs are intended to use gene therapy approaches to deliver functional genetic material to affected retinal tissues. The company’s assets remain in the research and clinical-development stages and are not broadly marketed commercial products. Opus Genetics was established in 2021 and has pursued the development of treatments for rare ophthalmic diseases through internal research and collaborations. The company is headquartered in the United States and focuses primarily on advancing potential therapies through preclinical and clinical testing for patients with inherited retinal diseases.AI Generated. May Contain Errors. Read More Opus Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreIRD MarketRank™: Opus Genetics scored higher than 69% of companies evaluated by MarketBeat, and ranked 236th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOpus Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 15 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOpus Genetics has a consensus price target of $11.92, representing about 150.5% upside from its current price of $4.76.Amount of Analyst CoverageOpus Genetics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Opus Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opus Genetics are expected to grow in the coming year, from ($0.96) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Opus Genetics is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Opus Genetics is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOpus Genetics has a P/B Ratio of 21.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Opus Genetics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.24% of the float of Opus Genetics has been sold short.Short Interest Ratio / Days to CoverOpus Genetics has a short interest ratio ("days to cover") of 1.51, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Opus Genetics has recently increased by 15.27%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpus Genetics does not currently pay a dividend.Dividend GrowthOpus Genetics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.54 News SentimentOpus Genetics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Opus Genetics this week, compared to 6 articles on an average week.Search Interest11 people have searched for IRD on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat Follows3 people have added Opus Genetics to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Opus Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $213,749.00 in company stock.Percentage Held by Insiders11.70% of the stock of Opus Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions14.97% of the stock of Opus Genetics is held by institutions.Read more about Opus Genetics' insider trading history. Receive IRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opus Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRD Stock News HeadlinesHead-To-Head Review: ProQR Therapeutics (NASDAQ:PRQR) versus Opus Genetics (NASDAQ:IRD)September 26 at 4:58 AM | americanbankingnews.comWall Street Zen Downgrades Opus Genetics (NASDAQ:IRD) to SellSeptember 26 at 1:25 AM | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.September 28 at 1:00 AM | Awesomely (Ad)Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?September 16, 2026 | insidermonkey.comOpus Genetics consensus price target increased 21.47% to $12.98September 16, 2026 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Pyxis Oncology (PYXS) and Opus Genetics (IRD)September 10, 2026 | theglobeandmail.comWedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform RatingSeptember 10, 2026 | marketscreener.comMOpus Genetics (NASDAQ:IRD) CFO Sells $127,120.00 in StockSeptember 9, 2026 | insidertrades.comSee More Headlines IRD Stock Analysis - Frequently Asked Questions How have IRD shares performed this year? Opus Genetics' stock was trading at $2.01 at the start of the year. Since then, IRD stock has increased by 136.8% and is now trading at $4.76. How were Opus Genetics' earnings last quarter? Opus Genetics, Inc. (NASDAQ:IRD) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.02. The business earned $0.76 million during the quarter, compared to the consensus estimate of $2.63 million. Opus Genetics had a negative trailing twelve-month return on equity of 338.88% and a negative net margin of 1,091.82%. Who are Opus Genetics' major shareholders? Opus Genetics' top institutional investors include BlackRock Inc. (3.77%), Nantahala Capital Management LLC (3.70%), Trails Edge Capital Partners LP (3.32%) and ADAR1 Capital Management LLC (2.16%). Insiders that own company stock include Fighting Blindness Foundation, Cam Gallagher, Cam Gallagher, George Magrath, Benjamin R Yerxa, Benjamin R Yerxa, Robert E Gagnon, Ashwath Jayagopal, Joseph K Schachle and Rabourn Amy Zaremba. View institutional ownership trends. How do I buy shares of Opus Genetics? Shares of IRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2026Today9/28/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 3 weeks, IRD's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IRD Previous SymbolNASDAQ:IRD CIK1228627 Webwww.opusgtx.com Phone248-957-9024Fax240-268-5310Employees28Year Founded2018Price Target and Rating Average Price Target for Opus Genetics$11.92 High Price Target$20.00 Low Price Target$7.00 Potential Upside/Downside+150.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.59 million Net Margins-1,091.82% Pretax Margin-1,091.82% Return on Equity-338.88% Return on Assets-150.13% Debt Debt-to-Equity RatioN/A Current Ratio12.19 Quick Ratio12.19 Sales & Book Value Annual Sales$14.20 million Price / Sales27.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book21.64Miscellaneous Outstanding Shares82,650,000Free Float72,978,000Market Cap$393.41 million OptionableN/A Beta0.58 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:IRD) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
